story of the week
Endocrine Therapy With or Without Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+/HER2− Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial
J. Clin. Oncol 2023 May 19;[EPub Ahead of Print], K Kalinsky, MK Accordino, C Chiuzan, PS Mundi, E Sakach, C Sathe, H Ahn, MS Trivedi, Y Novik, A Tiersten, G Raptis, LN Baer, SY Oh, AB Zelnak, KB Wisinski, E Andreopoulou, WJ Gradishar, E Stringer-Reasor, SA Reid, A O'Dea, R O'Regan, KD Crew, DL HershmanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.